&#xa0;
[normal]Written evidence submitted by [bold]AstraZeneca[bold] (AMR0018)[bold]&#xa0;[bold]Executive summary[bold]&#xa0;[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]About AstraZeneca[bold]&#xa0;
[normal]&#xa0;[bold]Terms of Reference[bold]&#xa0;
[normal]How has antimicrobial resistance developed in the past decade?
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]What are the gaps in our knowledge about antimicrobial resistance?
[normal]&#xa0;
[normal]&#xa0;
[normal]Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]What measures (including behavioural change) 
[normal]have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]Recommendations for action[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;[bold]&#xa0;[bold]&#xa0;
[normal]&#xa0;[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;[bold]November 2013
[normal]&#xa0;[bold]&#xa0;[bold]&#xa0;[bold]&#xa0;[bold]&#xa0;[bold]&#xa0;[bold]&#xa0;[bold]REFERENCES[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]Annual Report of the Chief Medical Officer Volume Two, 2011. Infections and the rise of antimicrobial resistance. Available at: 
[normal]https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf
[normal]. Accessed September 2013
[normal] World Health Organization Regional Office for Europe. Self-prescription of antibiotics boosts superbugs epidemic in the European Region. November 16, 2012. Available at: 
[normal]http://www.euro.who.int/en/what-we-publish/information-for-the-media/sections/latest-press-releases/self-prescription-of-antibiotics-boosts-superbugs-epidemic-in-the-european-region
[normal]. Accessed September 2013
[normal] Office of Health Economics. New drugs to tackle antimicrobial resistance: analysis of EU policy options. April 2011. Available for download from: 
[normal]http://www.ohe.org/page/index.cfm
[normal]. Accessed September, 2013
[normal] Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating Antimicrobial Resistance: Policy Recommendations To Save Lives. Clin Infect Dis 2011:52(Suppl 5):S397-428
[normal] Projan S. (2003) Why big pharma is getting out of AB discovery, Current Opinion in Microbiology 2003, 6:427-430
[normal] Smith R and Coast J, The true cost of antimicrobial resistance, British Medical Journal 2013;346
[normal]http://www.bmj.com/content/346/bmj.f1493
[normal] 
[normal] Sally Davies, The drugs don’t work, Sunday Times, 15 September 2013
[normal]http://www.thesundaytimes.co.uk/sto/newsreview/features/article1313446.ece
[normal] 
[normal] Innovative
[normal] Medicines Initiative, 
[normal]9th Call for Proposals 2013
[normal], July 2013. 
[normal]http://www.imi.europa.eu/webfm_send/914
[normal] Health Protection Agency, Healthcare-Associated Infection and Antimicrobial Resistance: 2010-2011, August 2012 
[normal]http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912
[normal] 
[normal] Department of Health, UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, 10 September 2013. Available at 
[normal]https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf
[normal] House of Commons Science and Technology Committee,  Uncorrected Transcript Of Oral Evidence from the Chief Medical Officer, Department of Health, HC 921-I, Published 11
[normal]th
[normal] February 2013
[normal]http://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm
[normal] 
[normal] World Health Organisation. World Health Day 2011: Urgent action necessary to safeguard drug treatments. News Release. 06 April 2011 
[normal]http://www.who.int/mediacentre/news/releases/2011/whd_20110406/en/index.html
[normal] World Economic Forum, Global Risks 2013: Eighth Edition. Published 2013. Available at 
[normal]http://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/
[normal] Accessed September 2013
[normal] Infectious Diseases Society of America, The 10 x 20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020, Clin Infect Dis. (2010) 50 (8): 1081-1083
[normal]http://cid.oxfordjournals.org/content/50/8/1081.full.pdf+html
[normal] 
[normal] Elaine A Irving presentation, New Drugs for Bad Bugs – Regulatory aspects in Innovative Medicines Initiative projects, November 2010
[normal]http://www.efpia.eu/uploads/Modules/Documents/nd4bb_overview_jan_2013.pdf
[normal] 
[normal] Pew Health Group, Fact sheet:  The Generating Antibiotic Incentives Now Act of 2011, 20 September 2011 
[normal]http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf
[normal] BBC News Online, Antibiotics resistance 'as big a risk as terrorism' - medical chief, 11 March 2013
[normal]http://www.bbc.co.uk/news/health-21737844
[normal]